Pathways involving PRPF8, such as the PRPF8–PIRH2–p53 pathway [63], have notable limitations, with their effects primarily confined to specific tumor types, and the efficacy of different pathways varies significantly across tumors. This evidence concerns the gene RCHY1 and neoplasm.